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ABSTRACT 
THE RELATIONSHIP BETWEEN DIRECT TO CONSUMER MARKETING AND THE SELF-
PERCEPTION OF GERD SYMPTOMS IN THE YOUNG ADULT POPULATION 
Sheila Kumar (Sponsored by Priya Jamidar). Division of Digestive Diseases, Department of Internal 
Medicine, Yale University School of Medicine. New Haven, CT. 
The purpose of this study was to determine the prevalence of gastroesophageal reflux d isease 
(GERD) symptoms in a young adult population of university students and to examine the relationship 
between direct-la-consumer marketing and the self-perception ofGERD symptoms. 
GERO is defined as the spectrum of disease usually producing symptoms of heartburn and 
ac id regurg itation. Previous studies have varied prevalences in the adult population ranging from 5% 
to 45%, depending on the method of diagnosis. However, very little is known about the prevalence of 
GERD in the young adult population. Proton pump inhibitors (PPIs) are widely utilized to control 
GERD symptoms, and have been available without a prescription since 2003. During this time period, 
the use of direct-to-consumer (DTC) marketing of prescription medications was permitted in the 
United States. The prevalence or GERO in the young adul t population, as wel l as the impact of OTC 
advertising on the self-reporting of GERO symptoms, is largely unknown. 
A group-adm inistered questionnaire of 168 graduate and undergraduate students at Yale 
University was performed between September 2006 and December 2006. The mean age of 
respondents was 22.26 years. 68.64% of respondents were female. When using a diagnostic 
. qualification of mild symptoms at least one day a week, 3.57% of the subject popu lation reported 
heartburn symptoms, 8.92% reported regurgitation symptoms, and 1.79% reported both heartburn and 
regurgitation symptoms. 92.3% of respondents reported exposure to DTC ads, with 89.83% of 
respondents exposed to PP J advertisements. There was no correlation between exposure to 
advertisements for heartburn/reflux medications and the self-reporting ofGERD symptoms. 
The prevalence ofGERD symptoms in thi s young adult population is lower than that reported 
in adult populations. Direct-la-consumer marketing does not appear to influence the way this 
population perceives GERD symptoms. 
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I 
Introduction 
Gastroesophageal reflux is defined as the movement of gastric contents from the stomach 
to the esophagus, and GERD (gastroesophageal reflux) is defined as the spectrum of disease 
usually producing symptoms of heartburn and acid regurgitation (I ) . 
PATHOPHYSIOLOGY 
Reflux occurs when acidic stomach contents contact with the esophagus. The arrival of a 
bolus offeod in the stomach causes distension and mucosa l irritat ion of the stomach epitheli um. 
Th is leads to the secret ion of protons by proton pumps (H+IK+ ATP-ase) in the parieta l cells. 
Histamine, gastrin, and acetylcholine regulate the activity of these pumps. Reflux occurs 
transiently in the normal patient, but is generally prevented by a three-stage system. 
The first component of this system is the anatom ical anti-reflux barrier. The lower 
esophageal sphincter (LES), a 3-4 cm long section of tonically contracted esophagus, generates 
pressure between 10-30 mm Hg above the intragastric pressure in order to prevent the reflux of 
gastric contents bac k into the esophagus (2). The pressure generated by the LES is affected by 
several factors- for example, the presence of protein or honnones such as gastrin cause an 
increase in the pressure, while the presence of fat or honnones such as secretin cause a decrease 
in the pressure. Diurnal variation also exists, such that the LES pressure is highest at night and 
lowest after meals (J). Transient LES relaxation occurs in nonna l subjects during swa llowing and 
belching, to a llow for the passage of food and a ir (3). In addition to the pressure generated by the 
LES, further protection is afforded by the crura l diaphragm which surrounds the proximal end of 
the LES. The .crural diaphragm exerts an additional pressure to compensate when LES pressure is 
not enough to prevent reflux. 
The second mechanism to prevent reflux is esophageal acid clearance. The first 
component of this is volume clearance, or the actual c learance of gastric contents from the 
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esophagus. This occurs through two waves ofperistai sis. The first wave of peristalsis is initiated 
by swallowing, while the second wave of peristalsis is initiated by the esophageal distension from 
reflux. This second wave thus plays a less beneficial role than the initia l peristalsis. Volume 
clearance is enhanced by gravity, which assists with bolus clearance through peristalsis. The 
second component of this anti-reflux mechanism is actual acid clearance, which refers to the 
titration of acidic esophageal contents to a neutral level by the addition of a base. Saliva plays an 
important role in this, as it functions as a weak base. The esophagosaJivary reflex, which refers to 
the production of saliva after the majority of a bolus has been cleared through volume clearance, 
results in the addition of this weak base to the remaining acidic esophageal contents (4). 
The third tier of mechanisms to prevent reflux is tissue resistance. This consists of pre-
ep ithe lia l, ep ithe li a l, a nd post-epithelia l sys tems. The pre-e p ithe li a l system does 
not offer mu ch protection aga in st acidic conten ts in the esophagus, as cells in 
thi s laye r cann o t secrete any buffer (in contras t t o ce ll s found in this layer in 
the s tomac h , for exam pl e, which c an sec rete bicarbonate). The epith e lial layer 
offers pro tec ti on through a thick layer of non-ke ratin ized squ a mou s ep ith e lium 
con nected t hough numerous ti ght ju ncti ons, that serves as an anatomic barrier 
th roug h whi ch acid ic io n s ca nn ot pass. In addition , the ce ll s in this layer secrete 
severa l buffers . Bicarbonate is secreted through a sOd ium - ind epend e nt chlor id e-
bi carbonate exchanger. Phosphate and negative ly c ha rged prote in s a re a lso 
secreted. The ce ll s in thi s layer al so have the abil it y to ac ti ve ly re move proto ns, 
through the act ions of a sod iu m-p rot o n exchange r a nd a sodiu m-dependent 
c h lo rid e-bicarbonate exchange r (5,6). The post -epithe li a l laye r offe r s protectio n 
through the effects of esophagea l bl ood flow , whi c h removes protons from a nd 
ca rri es bica rbo nate t o th e esop hagus. 
In gastro-esophageal reflux, sevt:ral or all of these intrinsic anti-reflux mechani sms may 
fail. In tenns of the anatomical anti-reflux barrier, transient relaxations of the LES occur nonna lly 
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during swallowing and belching. as explained above; the role of these relaxations in GERD is 
controversia l. Whether they are experienced more often by patients with GERD remains unclear, 
with research supporting as well as challenging that theory (7). However, the probability of reflux 
episodes during episodes of transient relaxation is greater in patients with GERD than in nonnal 
patients (7). Stress reflux and free reflux are types of gastroesophageal reflux that are associated 
with lowered LES pressures. In stress reflux, a sudden increase in intrabdominal pressure from 
coughing or straining overcomes an initially lowered LES pressure, and thus results in reflux. 
Free reflux occurs when there is no change in intra-abdominal pressure, yet reflux still occurs, 
and is usually associated with an already lowered LES pressure (1). 
Failures ·of esophageal ac id clearance can be due to failures of volume clearance or acid 
clearance. One mechanism that may contribute to a failure of volume c learance is related to 
esophagitis. It has been noted that patients with severe esophagitis have a higher prevalence of 
peristaltic dysfunction that patients with mild esophagitis (8). As esophagitis is correlated with 
reflux, it may be that reflux causes the increased peristaltic dysfunction, which then cycles back 
to cause an increasing amount of reflux. Or it may be that these pat ients have an innate peristaltic 
dysfunction that then predisposes them to esophagitis and reflux. 1t is worthwhile to mention 
again the role that gravity plays in bolus vo lu me clearance to the stomach-thus, the initial 
therapy for GERD that involves raising the head of the bed and the avoidance of lying sup ine 
after meals all draw upon grav ity for their efficacy. Failures of acid clearance may be secondary 
to a decreased esophagosalivary reflex, which has been demonstrated in patients with reflux 
esophagit is (9). 
CLINICAL SYMPTOMS 
Reflux has a wide spectrum of clinical symptoms. Patients commonly experience 
heartburn, acid regurgitation, and dysphagia. Heartburn is retrostemal burning discomfort, that 
radiates toward the neck, and is generally experienced postprandially. This sensation may be 
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exacerbated by recumbency, bending over, large meals, spicy foods, chocolates, alcohol, and 
citrus products (1). Dysphagia is reported by more than 30% of patients with GERO (10). This 
symptom may be secondary to esophageal peristalsis or heightened esophageal sensitivity. When 
associated with bolus impaction, it may be due to a peptic stricture, Schatski ring, esophageal 
inflammation, or esophageal cancer (1,11). Water brash (hypersalivation) may occur, due to a 
sudden increase in salivary production secondary to increased esophageal acidity. Odynophagia, 
se<:ondary to increased sensitivity of the esophageal mucosa, may occur, and is usually associated 
with severe esophagitis. Belching, hiccups, nausea, vomiting, and globus (constant perception of 
a lump in throat) may be experienced (10.12). Extraesophageal symptoms include chest pain that 
is similar in its characteristics to angina pectoris (1). Patients may also experience posterior 
laryngitis, though whether re flux itself is the spec ific cause is unknown ( 10). Finally, patients 
may experience reflux~induced asthma (13). 
Barrett's esophagus is a known complication ofG ERD. This condition occurs when 
columnar epithelium rep laces the nonnal squamous epithelium of the esophagus, and has been 
hi storically associated with an increased risk of esophageal adenocarcinoma (14). However, 
recent studies have questioned the incidence of increased risk of adenocarcinoma in patients with 
Barrett's esophagus ( 15). 
I?IAGNOS IS 
The diagnosis ofGERD is often made on a c linical bas is. Initia l therapy usually involves 
lifestyle interventions, which include elevation of the head of the bed, e limination of spicy foods, 
and exercise and diet strategies for weight loss. If these interventions do not work, initial medical 
therapy is usually aimed at ac id suppression, and includes proton pump inhibitors (PPIs) and H2 
antagoni sts. If e ither of these therapies alleviates symptoms, the diagnosis of GERD may be 
assumed. A trial for the empiric use of proton pump inhi bitors (PPls) demonstrated a sensitivity 
of up to 84% for the diagnosis ofGERD (16, 17). In tria ls investigating the use ofa proton pump 
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inhibitor in patients with non-cardiac chest pain, a 7-day trial with omeprazole had a sensi ti v ity 
of 78% and speci fi c ity of 86% for the diagnosis of GERD (J 8). Generally, af'teran 
empiric trial with acid suppression, further invasive investigations are only be done for patients 
with an unclear diagnosis secondary to mixed reflux and gastrod uodenal symptoms or atypical 
symptoms, persistence of symptoms with a trial of medication, symptoms suggestive of severe 
esophagitis such as hematemesis or persistent dysphagia, or when other diagnoses (such as 
esophageal malignancy or infective or drug-induced esophagitis) are entertained. 
Endoscopy may be utilized in the diagnosis ofGERD, though again, wi th the advent of 
PPI trials, endoscopy is usually used only to demonstrate the presence of Barrett's esophagus. 
Endoscopic find ings correspond to the severity of the disease, with initial findings including 
edema, erythema, and friability, and later findings consisting of erosions and finally, ulcers. 
Howevei~ while the sensitivity is 90-95%, the spec ificity is on ly 60% ( 19). Esophageal biopsy 
may be done in conjunction with endoscopy to further identify Barrett's esophagus. 
Esophageal pH measurement is the gold standard for the demonstration of pathologic 
reflux . This method can demonstrate the relat ionship between reflux episodes and associated 
symptoms. T hough invasive tests (such as pH measurement or endoscopy) exist, the diagnosis of 
GERD is primarily made on a clinical basis, 
TREATMENT 
The treatment ofGERD consists of several strategies. The initial treatment is usual ly 
lifestyle alteration. This includes head of bed e levation, smoking cessation, dietary changes 
(i ncluding the e limination or restrict ion of fatty or spicy foods), restriction of a lcohol, weight 
loss, and the restriction of meals immed iately before bedtime. Initi ally, patients may try antacids 
or over the counter H2-receptor antagonists. H2 receptor antagonists have been shown to 
significantly decrease heartburn (20). Initial prescribed therapy is usua lly a tria l of proton pump 
inhibitors. PPIs have been found to be superior to H2-antagonists in the treatment of GERD, with 
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better relief of symptoms and a return to Donnal esophageal histology (20). Should patients 
remain refractory to PPIs, a switch to a different brand ofPPI or an addition of a second dose may 
be warranted. Maintenance therapy usually consists of a long-term regimen ofPPIs. 
PREVALENCE 
In 1976, the incidence of symptomatic gastroesophageal reflux was evaluated through the 
distribution of a questionnaire that revealed that 7% of the subj ects experienced heartburn daily. 
14% noted heartburn weekly. and 15% experienced it once a month, giving a total of36% of 
subj ects baving heartburn at least monthly. This study also noted that age, sex, and hospitalization 
did not significantly affect incidence, and that the most common precipitating factors included 
fried foods, "spicy" foods, and alcohol (21). 
Currently, the prevalence ofGERD varies, depending on the method of diagnosis. 
However, despite which method is used, the prevalence does appear fairly common. Locke et a l 
conducted a validated self-report questionnaire with 2200 subjects in Olmstead County, 
Minnesota, that demonstrated a prevalence of 19.8% of week ly heartburn and/or regurgitation 
(22). In a population in Finland, Isolauri et al found a prevalence ofGERD (defined as daily 
heartburn and/or regurgitation) of 10.3%, noting th at sign ificant risk factors included age, obes ity, 
pregnancy, and cigarette smoking (23). Interestingly, the prevalence of GERD appears to be 
lower in Asian and African nations. For example, in 1999, a cross-sectiona l survey of subjects in 
Singapore demonstrated a mean prevalence of reflux-type symptoms (heartburn and/or acid 
regurgitation) of5.5%, with a prevalence of7.5% in Indian subjects, 0.8% in Chinese subjects, 
and 3.0% in Malay subjects (24). The reasons behind this global difference are unclear, though 
the authors postulated that there may be unknown geneti c factors. 
Most of this type of research has been done on the prevalence of GERD in the adult and 
pediatric populations, while less research has been done on its presence in the young adult 
population. The research that has been done suggests that GERD is common in this population as 
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well. Somi et al performed a cross·sectional study on a young population in Tabriz, Iran, with a 
mean age of22.48. In this population, the prevalence of heart bum andlor acid regurgitation 
experienced weekly was 6.3% and experienced monthly was 13%. The symptoms were most 
often rated as mild to moderate. The authors noted that there was no significant gender or age 
difference; however, risk factors included a higher BMI and the use of coffee and tea. Also noted 
was the fact that GERO symptoms were reported less in subjects with no family history of upper 
gastrointestinal disease, as well as in students in "higher rank fields" (25). 
The prevalence of GERD appears to be increasing over time. El-Serag et a l reported a 
signific!,!nt increase in hospitalization rates for GERD from 1970 to 1995 (26). The authors of the 
paper described above that investigated the prevalence of reflux-type symptoms in Singapore re-
interviewed the same subjects 5 years later. The prevalence had increased to 10.5% -- 11.7% in 
Indian subjects, 9.4% in Chinese subjects, and 11.6% in Malay subjects (27). A systematic 
statistical analysis of population-based stud ies investigating the prevalence of at least weekly 
heartburn and/or regurgitation, studies investigating the prevalence ofGERD in the same 
population at separate times, and studies investigating the prevalence ofGERD symptoms and 
esophagitis in primary and secondary care demonstrated a significant upward trend in the 
prevalence of reflux symptoms (28). 
THE GROWING PRESENCE OF ADVERTISEMENTS 
Marketing for medications has changed greatly in the past thirty years, with a significant 
increase in direct to consumer advertising. An increasing amount of research is being performed 
to investigate the effects of this advertising on consumer perceptions. Much of this research has 
focused on the FDA Modernization Act of 1997, which dictated no limit on money spent for the 
advertisement of a medical condition and a treatment. It has been proposed that this act led to a 
significant increase in the amount of money put into advertisements by pharmaceutical 
companies. However, whether this act was directly responsible for this increase remains 
controversial, with some research pointing to the fact that spending in this sector began to 
increase before 1997, when the act was passed (29). Whether or not the act was the most 
significant factor in the increase in the amount of money spent in this sector, it is clear that 
funding for marketing has increased in recent years. In 2000, phannaceuticaI companies spent 
approximately $2.5 billion on direct to consumer marketing, nearly triple the amount spent in 
1996 and a disproportionately higher amount than that spent on other forms of marketing (29). 
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Different advertising methods are used in marketing toward the consumer. A content 
analysis of advertisements for prescription drugs from 1989 to 1998 by Bell et al demonstrated a 
dramatic increase in the number of new advertisements and brand introductions, with the most 
common appeals being effectiveness, symptom control, innovativeness, and convenience. 
Interestingly, they found while most ads were gender-neutral, those that were not tended to be 
directed toward women (30). Whether this marketing presents a clear and unbiased picture to the 
consumer has been the subject of much debate. Research done by Kaphingst et al has shown 
limitations of television advertisements that may lead to possible misinterpretation by the 
consumer. These include a greater amount of time spent on benefits rather than risks, the use of 
both medical and lay terms that may pose a problem to the consumer with limited literacy ski lls, 
the presentation of possible risks in one continuous fashion especially when accompanied by only 
positive or neutral (rather than negative) images, and an emphasis on the advertised medication 
rather than on the medica l cond ition the medication was meant to treat (31). A study by Huh et al 
that examined direct to consumer websites showed that while a balanced amount of information 
regarding both risks and benefits was presented, the modes of presentation differed. For example, 
infonnation regarding benefits of a medication was more easily accessible than information 
regarding ri sks. This may affect the consumer's perception of that medication (32). 
Despite the controversy regarding whether direct-to-consumer marketing fairly 
and accurately provides information, it is clear that advertisements for medications affect 
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consumers. Exactly how the increased amount of marketing aimed at the consumer 
affects consumer perception of disease and medications has been investigated in several 
studies. 10 a random-digit dialing telephone survey with a random household member 
selection procedure, subjects exhibited a mean awareness of advertisements of3 .7 out of 
10 drugs. This awareness was associated with prescription drug use, media exposure, 
positive attitudes toward direct-la-consumer marketing, poorer heaJth, and insurance 
status. Subjects were noted to hold several misconceptions about the advertising of 
medications, including the idea that only "completely safe" drugs could be marketed. 
Finally, the authors noted that advertisements led to 33% of the subject population to ask 
physicians for infonnation regarding a drug, and 20% of the subject population to ask for 
a specific prescription (33). The same research group looked at patients' reactions to a 
scenario where their physician refused an advertisement-motivated drug request. 
Interestingly, the most likely reaction was disappointment. A lower percentage of the 
patients surveyed were likely to try to persuade the physician to prescribe the medication, 
or change physicians in order to find one who would prescribe the drug. From these 
responses, the authors concluded that since a large percentage of patients would react 
negatively to a physician'S refusal to consent to an advertisement-motivated drug request, 
ft was clear that physicians need to be aware of patients' attitudes toward advertising-
induced drug requests (34). Further research by Mintzes et al demonstrated that a greater 
percentage of patients with a higher rate of exposure to OTC marketing requested 
advertised medications than did patients with a lower rate of exposure. Furthermore, 
patients that requested medications marketed in this fashion were more likely to receive 
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one or more new prescriptions for the requested medication or an acceptable alternative, 
than were patients who did not request these medications (35). 
While much research has been conducted on the effect of direct to consumer 
marketing in general, few investigations specifically aimed towards GERD have been 
completed. One study looked at how DTC marketing influences patients' shift from one 
PPI to another. The investigators completed a retrospective cohort study of health claims 
data from a large database that monitored claims for health benefit programs oflarge 
employers. The claims for lansoprazole and omeprazoie were investigated. DTC 
marketing was investigated by assigning an advertising level by geographic location, 
such that areas were divided into high and low expenditure categories. The authors of the 
study noted that omeprazole. but not lansoprazoie, was advertised during the year in 
which the study took place. While switching from one PPJ to another was common for 
the naIve PPJ user, switching specifically from lansoprazole to omeprazole (61.9%) was 
more common than switching from omeprazole to lansoprazole (38.1 %). The authors 
postulated that this difference may have been related to the increased level of marketing 
for omeprazole. Logistic regression modeling demonstrated that a high level of direct to 
consumer marketing was associated with a switch to the advertised product. In addition, 
the presence of advertising for omeprazole was a significant predictor for switching to 
omeprazole. The authors did note several limitations to the study. First, the current PPI 
market is more complicated than the market at the time of the study (1998), and the 
existence of more sophisticated advertising campaigns, and tiered cost-sharing and 
therapeutic switching programs under specific health insurance plans, may make the data 
from the study inapplicable to today's.patient population. Second, the study excluded 
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patients eligible for Medicaid or over the age of 65 years, who may have different 
patterns afuse that could have affected the analysis. Third, the investigators were unable 
to control for other variables that could have affected patient product use, such as 
pharmaceutical sampling, patient education level, and patient income. Finally, the use of 
the database did not alJow for the analysis of the degree of appropriate PPI switching. For 
example, part of the motivation to switch from one PPI to another could have been the 
persistence of worrisome symptoms that were not being effectively controlled by the 
initial PPJ. Despite these limitations, this study demonstrated a possible relation between 
direct to consu~er marketing and switching from one PPI to another (36). Fendrick et al 
conducted a 3-month observational study that detennined that consumers accurately self-
selected to use omeprazole for frequent heartburn, complied with the product label that 
called for a 14-day regimen, and sought physician help for use of more than14 days of the 
medication (37). This may indicate that consumers respond accurately to advertisements 
for GERD medications. 
HYPOTHESIS/AIMS 
Our hypothesis is that a relationship may exist between the se lf-perception of reflux 
symptoms and the increasing prevalence of advertisements for medications. Our aim was to 
determine the prevalence ofGERD symptoms and the level of DTC advertisement exposure in a 
young adult population. We sought to determine if advertisement exposure to PPls influenced the 
perception ofGERD symptoms. 
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METHODS 
A questionnaire regarding the level and severity of GERD symptoms and the exposure 
and influence ofDTC advertisements was presented to Yale Univers ity students. This study was 
approved by the Human Investigations Committee at the Ya le University School of Medicine. 
STUDY POPULATION 
Subjects were recruited from undergraduate and graduate classes at Yale University. The 
Inclusion criteria consisted of undergraduate or graduate students at Yale Univers ity and 
completi on of the questionnaire, while exclusion criteria consisted of non-English speaking 
subjects and subjects under the age of 18 or over the age 0[30. 
STUDY DESIGN 
A questionnaire was designed to assess the self-perception of GERD symptoms, as we ll 
as possible effects ofDTC advertisements on patients' self-perception of disease, First, the scale 
for the self-perception of GERD sym ptoms (question I) was utilized from a recent study that 
va lidates a simple diagnostic questionnaire for gastroesophageal reflux disease symptoms, with 
the permiss ion of the authors of that study (38), These symptoms were stratified into two 
categories: the heartburn symptoms were defi ned as "a burning fee ling behind your breastbone" 
and "pain behind your breastbone," whi le the regurgitation symptoms were defined as "an acid 
taste in your mouth" and "unpleasant movement of materia l upwards from your stomach", The 
subjects were asked to detail the frequency of these symptoms over the past 4 weeks, using the 
fo llowing sca le: "did not have", " less than one day a week", "one day a week", ''2·3 days a 
week", "4-6 days a week", "daily", The subjects were then asked to detai l the severity of these 
symptoms over the past 4 weeks, us ing the fo llowing scale: "did not have", "very mild", "mild", 
"moderate"> "moderately severe", or "severe" , In addition to these survey questions, 15 questions 
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(questions 2~ 16) that were designed to identify a possible effect of advertisements for medications 
on the self-perception of reflux were developed. These questions included three questions 
designed to look at the subjects' familiarity with advertisements for any medications, and three 
questions designed to look at the subjects' familiarity with advertisements specifically for reflux. 
Five questions were asked about the use of reflux medications, physician visits for reflux 
symptoms, and whether the subjects believed they were influenced by advertisements for reflux . 
medications. Demographic questions included the subjects' age, sex, alcohol and tobacco history, 
and use of prescription and over-the-counter medications. All responses were anonymous. The 
questionnaire was tested on a focus group (n= 19), whose suggestions were incorporated into the 
final questionnaire. (Please see end of document for the GERD Questionnaire.) 
Initially, the course coordinator for the departments of English, Anthropology, History, 
Engineering and Applied Sciences, American Studies, and African-American Studies at Yale 
Un iversity and the School of Public Health at Yale University were contacted in order to obtain a 
subject group that was representative oftoday's young adult popu lation, based on sex and race. 
After obtaining approval from the department heads, professors were contacted to ensure that the 
distribution of questionnaire to their classes would be allowed. At the end of class, the purpose of 
the study was explained, and the questionnaire and an infonnation sheet for participation in a 
research project were distributed to each student in that particular class. Completed 
questionnaires were collected that day. The results of each completed questionnaire were 
compi led in a database. 
(The development of the questionnaire was perfonncd by Shei la Kumar, Harry Aslanian 
M.D., and Priya Jamidar M.D. Distribution of the questionnaire and the compilation of the data 
was completed by the primary researcher, Sheila Kumar. Statistical analysis was performed by 
Shei la Kumar in conjunction with Dr. Valentine Njike at the Yale Prevention Research Center.) 
RESULTS 
DEMOGRAPmC INFORMATION 
169 subjects were studied, compris ing 116 females and 53 males, with a mean age of 
22.26 years. 
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28.6% of the subject group reported the use of prescription medications, most commonly 
birth control. 66.67% of this population reported using 1 medication, 31.25% reported 2 
medications, and 2.1 % reported 3 medications. Meanwhile, 18.5% of the total subject group 
reported the use over the counter medications, most commonly analgesics. 71 % of thi s population 
reported using I medication, 25.8% use 2 medications, and 3.2% use 3 medications. 
2.38% of the subject population smoke tobacco (75% of this population smoked less than 
1 pack ~r day, while 25% smoked greater than 1 pack per day). 75% of the subject population 
drink alcohol (13.49% drink 2-3 times a year, 48.4'1% drink 2-3 times a month, 37.3% drink 2-3 
times a week, and 0.79% drink daily). 
GERDSYMPTOMS 
The first symptom we investigated was "a burning feeling behind the breastbone!' 23.8% 
of the subject group reported this sensation, with the majority experiencing it < 1 day a week 
(575%) and rating it "very mild" (40%), The second symptom we investigated was "pain behind 
the breastbone:' 17,9% of the subject group reported this sensation, with the majority 
experiencing it < 1 day a week (70%) and rating it "very mild" (46,67%). The third symptom we 
investigated was "an acid taste in the mouth." 27.4% of the subject group reported this sensation, 
with the majority experiencing it < I day a week (60.9%) and rating it "very mild" (54.3%). The 
fourth symptom we investigated was "unpleasant movement of material upwards from the 
stomach:' 36,9% of the subject group reported this sensati on, with the majority experiencing it 
< I day a week (62,9%) and rating it "very mild" (41.9%). 
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For eacb category of symptoms (heartburn and regurgitation), we added up the scores for 
severity (0 = "did not have," t = " less than one day a week," 2 = "one day a week," 3 = "2-3 days 
a week," 4 = "4-6 days a week," and 5 = "daily") and frequency (0 = "did not have," 1 = "very 
mild," 2 = "mild," 3 = "moderate," 4 = "moderately severe," and 5 = "severe") for a final score. 
The minimum possible score was 0, while the maximum possible score was 20. We used two 
cutoff scores. First, a score of 8 corresponds to mild symptoms one day a week. This would be a 
c linically significant score, and would usually warrant intervention by a physician. We also used 
a score of 6, which corresponds to less stringent diagnostic criteria of e ither mild symptoms less 
than one day a week or very mild symptoms one day a week. This is also a cl inically relevant 
score. We believe that using these scores as a way to determine the subjects in our population 
who suffer from heartburn, regurgitation, or both heartburn and regurgitation, is valid because the 
diagnosiS of gastroesophagea l reflux di sease is a clinical diagnosis that is usually based on the 
patient's self-reporting of symptoms. 
Using a score of 8 as the cutoff, 3.57% (6) of the su bject population reported heartburn 
symptoms, 8.92% (15) reported regurgitation symptoms, and 1.79% (3) reported both heartburn 
and regurgitation symptoms. Using a score of6 as a cutoff, 20.24% (34) of the subject population 
reported heartburn symptoms, 27.38% (46) reported regurgitation symptoms, and 9.52% (16) 
reported both heartburn and regurgitation symptoms. 
Please see Figure I. 
16 
Figure I Frequency and Severity ofGERD Symptoms 
Freauency Severity 
"Burning feeling behind < I day aweek = 23 (57.5%) Very mild "" 16 (40%) 
the breastbone" "" 40 I day a week = 10 (25%) Mild = 12 (30%) 
(23.8%) 2-3 days a week = 5 (12.5%) Moderate = 10 (25%) 
4·6 days a week = 2 (5%) Moderately severe = 1 (2.5%) 
Daily = 0 Severe = I (2.5%) 
"Pain behind the < I dayaweek = 2 1 (70%) Very mi ld = 14 (46.67%) 
breastbone" = 30 (1 7.9%) I day a week = 6 (20%) Mild = 12 (40%) 
2-3 days a week = 2 (6.67%) Moderate = 3 (10%) 
4-6 days a week = I (3.33%) Moderately severe =: 0 
Daily = 0 Severe = I (3.33%) 
"An acid taste in the < I day a week = 28 (60.9%) Very mild = 25 (54.3%) 
mouth" = 46 (27.4%) I day a week = 12 (26.1%) Mild = )4 (30.4%) 
2-3 days a week = 5 (10.9%) Moderate = 4 (8.7%) 
4-6 days a week = I (2.2%) Moderately severe = 2 (4.3%) 
Daily = 0 Severe = I (2 .2%) 
"Unpleasant movement of < I day a week = 39 (62.9%) Very mild = 26 (41.9%) 
materia l upwards from the I day a week = 13 (2 1.0%) Mild = 22 (35.5%) 
stomach" = 62 (36.9%) 2-3 days a week =- 7 (11.3%) Moderate = 11 (17.7%) 
4-6 days a week =- 3 (4.8%) Moderately severe = 2 (3.2%) 
Daily = 0 Severe - I (1 .6%) 
EXPOSURE TO ADVERTISEMENTS FOR MEDICATIONS 
In the subj ect population, 92.3% (1 55) reported having been exposed to ads for 
m edications, with the most common mode of exposure through magazines/newspapers, the 
internet, and television (30.3%). P lease see Fi gure 2. 
Figure 2- Frequency of Modes of Exposure to Advertisements fOr Medications 
MODE OF EXPOSURE NUMBER OF SUBJECTS 
Magazin7s/newspapers + internet + television 47 (30.3%) 
Magazines/newspapers + te levision 3S (22.6%) 
Television 28 (18.1%) 
Mal1.!lzinesfnewsoaoers + internel + television + radio 20112.9%) 
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Of the subjects who reported exposure to ads for medications, 67.3% reported being able 
to recall the conditions that those med ications treated . The most common of these medications 
were heartburn/reflux (55.8%). Please see Figure 3. 
Figure 3- Frequency of Medical Conditions Recalled Through Advertisements 
RECALLED CONDITIONS NUMBER OF SUBJECTS 
Heartbumlreflux 63 (55.8%) 
Depression , 47 (41.6%) 
Sexual disorders 46 (40.7%) 
Finally. of the subjects who reported exposure to ads for medications, 54 .2% reported 
being able to recall the names of these medications. The most common class of names recalled 
was for sexual disorders (45.1 %), includ ing Cialis and Viagra. Please see Figure 4. 
Figure 4- Frequency o(Medicalions Recalled Through Advertisements 
NAMES OF MEDICATIONS RECALLED NUMBER OF SUBJECTS 
Sexual disorder medication 41 (45. 1%) 
(Cia lis, Viagra) 
Heartbumlreflux medication 36 (39.6%) 
(Prilosec, Pepcid, Turns) 
Depression medication 27 (29.7%) 
(Cymbalta) 
EXPOSURE TO ADVERTISEMENTS FOR HEARTBURNIREFLUX MEDICATIONS 
We also asked about exposure to advertisements for GERD specifically. In the subject 
population, 89.29% reported exposure to advertisements for heartburn/reflux, with television as 
the most common mode of exposure (56%). Please see Figure 5. 
Figure 5- Frequency of Modes of Exposure to Advertisements [or GERD Medications 
MODE OF EXPOSURE NUMBER OF SUBJECTS 
Television 84 (56%) 
26 (17.3%) 
Magazines/newspapers + television 
Maga~inesJnewspapers + internet + television 18 (12%) 
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Of the population that reported having been exposed to ads for heartbumlrenux 
medications, 38.7% reported being able to recall names of these meds, with Nexium as the most 
commonly recalled medication (27.7%). Of the population that reported having been exposed to 
ads for heartburn/reflux medications, 36.3% reported being able to recall details of these 
advertisements. The most commonly recalled detail, recorded by 32.3% of this population, was 
the slogan "The purple pill." Please see Figure 6. 
Figure 6- Frequency of Recalled Names ofGERD Medications 
NAMES OF MEDICATIONS RECALLED NUMBER OF SUBJECTS 
Nexium 18 (27.7%) 
Turns 17 (26.2%) 
Prilosec 15 (23. 1%) 
Pepcid 13 (20%) 
Prcvacid 10 (15.4%) 
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GERD SYMPTOMS AND EXPOSURE TO HEARTBURNIREFLUX ADS 
First, we investigated the relationship between exposure to advertisements for 
heartburn/reflex meds and self-reported GERO symptoms. According to responses on questions 
7 (familiarity with advertisements for heartburn/reflux medications), 8 (abi lity to recall names of 
heartburn/reflux medications), and 9 (ability to recall detai ls of advertisements for 
heartburn/reflux medications), we stratified three levels of exposure to heartburn/reflex 
advertisements into the following categories: "Low" = answered yes to question 7, "Moderate" = 
answered yes to question 7 and 8, "High" = answered yes to 7,8, and 9. For GERD symptoms, 
we scored the severity and frequency questions for the two parts of question 1 ( Heartburn and 
Regurgitation symptoms) as detailed above. When we used 8 as a cutoff score, we defined 
"Heartburn" as a score greater than or equal to 8 and "No Heartburn" as a score less than 8, 
"Regurgftation" as a score greater than or equal to 8 and "No Regurgitation" as a score less than 
8, and " Heartburn and Regurgitation" as a score of greater than or equal to 8 in both the 
"Heartburn" and "Regurgitation" categories and "No Heartburn and Regurgitation" as a score of 
less than 8 in both the "Heartburn" and "Regurgitation" categories. We defined these terms 
similarly when using 6 as the cutoff score. Again, a score of 8 wou ld generally warrant treatment 
by a physician, wh il e a score of 6 is also clinically relevant. 
First, we examined the relationship between levels of exposure to advertisements for 
~eartburnlreflux medications and the self-reporting of heartburn symptoms. Using both cutoff 
scores, subjects exposed to the low, moderate, and high leve ls of exposure to advert isements for 
heartburnlreflux medications were not more likely to report heartburn symptoms than subjects not 
exposed to these advertisements. 
Please see Figures 7 and 8. 
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Figure 7- Relationship Between Exposure (0 Advertisements for GERD Medicat ions and Self-Reported 
Heartburn Symptoms (Using a Score 0(8) 
Heartburn No Heartburn p-Value 
Low Level of Yes = 6 (3 .57) Yes = 144 (85.71) 1.0000 




Moderate Level of Yes = 2 (2.4 1) Yes = 63 (75 .90) 1.0000 
Exposure to No ~ 0 (0.00) No ~ 18 (21.69) 
HeartburnlRe flux 
Ads ' 
High Level of Yes = I (J .82) Yes = 36 (65.45) 1.0000 
Exposure to No ~ 0 (0.00) No = 18 (32.73) 
HeartbumlReflux 
Ads' 
Number of S ubJects (percentage) 
Figure 8- Relationship Between Exposure to Advertisements (or GERD Medications and Self Reported 
Heartburn Symptoms (Using a Score 0(6) 
Heartburn No Heartburn p-Value 
Low Level of Yes = 13 (7.74) Yes = 137(8 1.55) 0.6652 




Moderate Level of Yes = 7 (8.43) Yes = 58 (69.88) 1.0000 
Exposure to No ~ 2 (2 .41) No = 16 (19.28) 
HeartbumlRetlux 
Ads · 
High Level of Yes = 5 (9.09) Yes = 32 (58.1 8) 1.0000 
Exposure to No = 2 (3.64) No = 16 (29.09) 
Heartburn/Reflu x 
Ads· 
Number of SubJects (percentage) 
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We then examined the relationship between levels of exposure to advertisements for 
heartburn/reflux medications and the self-reporting of regurgitation symptoms. Using both cutoff 
scores, subjects exposed to the low, moderate, and high leve ls of exposure to advertisements for 
heartburn/reflux medications were not more likely to report regurgitation symptoms than subjects 
not exposed to these advertisements. Please see Figures 9 and 10. 
Figure 9- Relationship Between Exposure to Advertisements for GERD Medications and Sel[.Reported 
Regurgitation Symptoms (Using a Score orB) 
Heartburn No Heartburn p-Value 
Low"'Levelof Yes =: 15 (8.93) Yes = 135 (80.36) 0.3743 
Exposure to No = 0 (0.00) _No = 18 (10.71) 
Heartburn/Reflux 
Ads' . 
Moderate Level of Yes = 8 (9.64) Yes ;O 57 (68.67) 0.1910 
Exposure to No = 0 (0.00) No = 18 (21.69) 
HeartbumfReflux 
Ads' 
High Level of Yes = 4 (7.27) Yes ;o 33 (60.00) 0.2911 
Exposure to No = 0 (0.00) No = J8(32.73) 
HeartburnlReflux 
Ads' 
Number of Subjects (percentage) 
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Figure 10- Relationship Between Exposure toAdvertisemenls (or GERD Medications and Self.Reported 
Regurgitation Symptoms fUsing a Score 0(6) 
Heartburn No Heartburn v·Value 
Low Level of Yes = 13 (7.74) Yes = 137 (81.55) 0.6652 
Exposure to No - 2 (1.19) No = 16 (9.52) 
HeartbumIReflux 
Ads ' 
Moderate Level of Yes = 7 (8.43) Yes = 58 (69.88) 1.0000 
Exposure to No = 2 (2.41) No = 16 (19.28) 
Heartburn/Reflux 
Ads ' 
High Level of Yes = 5 (9.09) Yes = 32(58. 18) 1.0000 
Exposure to No - 2 (3.64) No = 16 (29.09) 
HeartburnlReflux 
Ads ' 
Number of SubJects (percentage) 
We also looked at the relationsh ip between leve ls of exposure to advertisements for 
heartburn/reflux med ications and the self-reporting of heartburn and regurgitation symptoms. 
Using both cutoff scores, subjects exposed to the low and moderate levels of exposure to 
advertisements for heartburn/reflux medications were not more likely to report heartburn and 
regurgitation symptoms than subjects not exposed to these advertisements. Please see Figures II 
and 12. 
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Figure J /- Relationship Between Exposure (a Advertisements (or GERD Medications and Self Reported 
fleartburn and Regurgitation Symptoms (Using a Score 0( 8) 
Heartburn AND No Heartburn AND p-Value 
Regurgitation Regurgitation 
Low Level of Yes = 3(1.79) Yes = 147 (87.50) 1.0000 
Exposure to No = 0 (0.00) No= 18 (10.71) 
HeartburnlReflux 
Ads· 
Moderate Level of Yes = 1 ( 1.20) Yes = 64 (77.1 J) 
1.0000 Exposure to No = 0 (0.00) No = J8 (2 1.69) 
Heartburn/Reflux 
A ds' 
High Level of Yes = 0 (0.00) Yes = 37 (67.27) Unable to be computed. 
Exposure to No = 0 (0.00) No = 18 (32.73) 
HeartbumIReflux 
Ads' 
Number of SubJects (percentage) 
Figure 12- Relationship Between Exposure (0 Advertisements (or GERD Medica/ions and Se/FReporled 
Hear/burn and Regurgitation Symptoms (Using a Score 0(6) 
Heartburn AND No Heartburn AND p-Value 
Regurgitation Regurgitation 
Low Level of Yes = 6 (3 .57) Yes = 144 (85.71) 0.5546 
Exposure to No ~ I (0.60) No = 17 (10.12) 
HeartbumfReflux 
Ads ' 
Moderate Level of Yes = 4 (4.82) Yes = 61 (73.49) 
1.0000 Exposure to No = I (1.20) No = 17 (20.48) 
Heartburn/Reflux 
Ads· 
High Level of Yes = 2 (3.64) Yes = 35 (63.64) 1.0000 
Exposure to No = I (1.82) No = 17(30.91) 
Heartburn/Reflux 
Ads · 
Number of Subjects (percentage) 
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Finally, we looked at the relationship between the responses to quest'ion 14, where we asked 
directly "Have advertisements for medications influenced your approach to heartburn or acid 
reflux symptoms?" and exposure to advertisements for medications for heartbumfreflux. We 
stratified the responses to question 14 into: Influence by Ads = responded yes to any part of thi s 
question and No Influence by Ads = responded no to th is question. Subjects exposed to the low, 
moderate, and hi gh levels of exposure to advertisements for heartburn/reflux medications were 
not morc likely to report having been influenced by these ads. Please see Figure 13. 
Figure J3- Relationship Between Self-Reporting oflnfluen ce by Advertisement and Exposure to 
Advertisements 
Influence by Ads No Influence by Ads p-Value 
Low Level of Yes = 115 (68.45) Yes = 35 (20.83) 0. 1584 
Exposure to No = II (6 .55) No = 7 (4.17) 
HeartbumlReflux 
Ads' 
Moderate Level of Yes = 54 (65.06) Yes = 11 (13.25) 0.0577 
Exposure to No = I I (13.25) No = 7 (8.43) 
HeartbumlReflux 
Ads" 
High Level of Yes = 30 (54.55) Yes = 7 (1 2.73) 0.1855 
Exposure to No ~ 11 (20.00) No = 7 (1 2.73) -
Heartburn/Reflux 
Ads' 
Number of Subjects (percentage) 
GERD SYMPTOMS AND PHYSICIAN V1SITSIUSE OF GERD MEDICATIONS 
We also investigated the relationship between self-reported GERD symptoms and the use 
of physician visits and med ications for GERD symptoms. As above, we stratified question I into 
Heartburn questions and Regurgitation ql:lestions, using both 8 and 6 as cutoff scores for 
Heartburn, Regurgitation, and Heartburn AND Regurgitation. 
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When using a cutoff score of 8, subjects who had seen a physician were more likely to 
report GERD symptoms and subjects who had received a prescription for GERD medications 
were marginally more likely to report heartburn symptoms. When using a cutoff score of 6, 
subjects who had taken a medication for GERD and who had seen a phys ician were both more 
likely to report heartburn symptoms. Please see Figures 14 and 15. 
Figure /4- Relationship Between Use ofGERD Medications/ physician Visits! Prescriptions fOr GERD 
Medications and Self-Reported Heartburn Symptoms (Using a Score 0(8) 
Heartburn No Heartburn p-VaJue 
Taken Medications Yes " 3 (1.79) Yes = 27 (16.07) 0.0708 
forGERD " No " 3 (1.79) No" 135 (80 .36) 
Seen a Physician for Yes = 3 (1.79) Yes = II (6.55) 0.0080 
GERO' No " 3(1.79) No " 151 (89 .88) 
Received a Yes = 2 (1 .19) Yes = 9 (5.36) 0.0508 
Prescription for . No " 4 (2.38) No" 153 (91.07) 
GERD Medication 
Number of SubJects (percentage) 
Fjgure J 5- Relatjonship Between Use oLGERD Medications! Physjcian Visits! Prescriptjons (or GERD 
Medications and Sel(Reported Heartburn Symptoms (Using a Score 0(6) 
Heartburn No Heartburn p-Value 
Taken Medications Yes=7(4.17) Yes=23( 13.69) 0.0067 
forGERD • No" 8 (4.76) No ~ 130 (77.38) 
Seen a Physician for Yes = 5 (2.98) Yes = 9 (5.36) 0.0035 
GERO ' No ~ 10(5.95) No = 144 (85 .7 1) 
Received a Yes = 3 ( 1.79) Yes = 8 (4.76) 0.0617 
Prescr iption for 
GERD Medication' 
No = 12(7. 14) No " 145 (86.31) 
Number of SubJects (percentage) 
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When using both cutoff scores of 8 and 6, subjects who had seen a physician for GERD 
symptoms and who had received a prescription for GERD medications were more like ly to report 
regurgitation symptoms. When using a cutoff score of8, subjects who had taken a medication for 
GERD were more likely to report regurgitation symptoms. Please see Figures 16 and 17. 
Figure 16~ Relationship Between Use ofGERD Medications/ Physician Visits! Prescriptions for GERD 
Medications and Self-Reported Regurgitation Symptoms (Using a Score 0(8) 
Regurgitation No Regurgitation p-Value 
Taken Medications Yes = 6 (3.57) Yes = 24 (14.29) 0.0304 
for GERD · No ~ 9 (5.36) No ~ 129 (76.79) 
. 
Seen a Physician for Yes '" 8 (4.76) Yes= 6 (3.57) 1.143E-06 
GERD' No~7(4. 1 7) No ~ 147 (87.50) 
Received a Yes = 5 (2.98) Yes = 6 (3.57) 9.613E-04 
Prescription for No = to (5 .95) No = 147 (87.50) 
GERD Medication -
Number of SubJects (percentage) 
Figure /7- Relationship Between Use ofGERD Medicotions! Physician Visits! Prescriptions for GERD 
Medications ond Self..Reported Regurgitation Symptoms (lJsing a Score o(6) 
Regur.e.itat ion No Re.e.ure.itation p-Value 
Taken Medications Yes = 8 (4.76) Yes=22 (13.to) 0.0906 
for GERD • No= 18(10.7 1) No= 120(7 1.43) 
Seen a Physician for Yes = 9(S.36) Yes ~5(2.98) 
U89E-05 GERD - No= 17{lO. 12) No = 137 (81.55) 
Received a Yes = 6 (3.57) Yes = 5 (2 .98) 0.0021 
Prescription for 
GERD Medication' 
No ~ 20 ( 11 .90) No"" 137(8 1.55) 
Number of SubJ ects (percentage) 
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When using both cutoff scores of 8 and 6, subjects who had seen a physician for GERD 
symptoms were more likely to report heartburn and regurgitation symptoms. When using a cutoff 
score of 6, subjects who had taken a medication for GERD were more likely to report heartburn 
and regurgitation symptoms. Please see Figures 18 and 19. 
Figure 18- Relationship Between Use ofQERD Medica/ions! Physician Visits! Prescriptions for GERD 
Medications and Sel(.Reporled Heartburn and Regurgitation Symptoms (using a Score 0(8) 
Regurgitation No Regurgitation D-Value 
Heartburn AND No Heartburn AND p-Value 
Regurgitation Regurgitation 
Taken MedicatiQns Yes ~ 2(1.19) YeF 28 (16.67) 0.0826 
forGERD • No ~ 1' (0.60) No ~ 137 (81.55) 
Seen a Physician Yes ~ 3 (1.79) Yes ~ II (6.55) 4.689E-04 
forGERD • No ~ O{O.OO) No~ 154(91.67) 
Number of SubJects (percentage) 
Figure J9- Relationship Between Use o(GERD Medications/ Physician Visits! Prescriptions fOr GERD 
Medications and Self-Reported Heartburn and Regurgitation Symptoms (Using a Score 0(6) 
Heartburn AND No Heartburn AND p-Value 
Regurgitation Regurgitation 
Taken Medications Yes = 5 (2.98) Yes = 25 (14.88) 0.0022 
forGERD • No = 2(1.19) No ~ 136 (80.95) 
Seen a Physician for YeF4 (2.38) Yes = 10 (5.95) 9.4I3E-04 
GERO· No~3 (1.79) No ~ 151 (89.88) 
Received a Yes -= 2 (1.19) Yes = 9 (5.36) 0.0685 
Prescription. for . No ~ 5 (2.98) No = 152 (90.48) 
GERD Medication 
Number of Subjects (percentage) 
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Fina lly. we looked at the re lationship between the responses to question 14, where we asked 
directly "Have advertisements for medications infiuenced your approach to heartburn o r acid 
reflux symptoms?" and physician visits for GERD symptoms/use of medications. None of these 
relationships were statistically significant. P lease see Figure 20. 
Figure 20· Relationship Between Use o(GERD Medications! Physician Visits! Prescriptions [or GERD 
Medications and Self-Reporting oUnfluence bv Ads 
Influence by Ads No Influence byAds p-Value 
Taken Medications YeF 26 (15.48) Yes = 4 (2.38) 0.1035 
forGERD' . No = 100 (59.52) No = 38 (22 .62) 
Seen a Physician fo r Yes = '11(6.55) Yes = 3 (1.79) 1.0000 
GERD' No = 115 (68.45) No = 39 (23.21) 
Received a Yes = 9 (5.36) Yes = 2 (1.19) 0.7328 
Prescription for 
GERD Medication ' 
No = II ? (69.64) No = 40(23.8 J) 
Number of SubJects (percentage) 
USE OF PRESCRIPTION/OTC MEDS AND EXPOSURE TO HEARTBURNIREFLUX ADS 
We investigated the relationship between taking prescription medication regularly 
(question 2) and the level of exposure to advertisements for heartbumlreflux. The subject 
population who reported having a low, moderate, or high level of exposure to heartbum/reflux 
ads was not statistica lly more like ly to a lready be taking prescription medications. Please see 
Figure 21. 
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Figure 21· Relationship Between Levels o(Exposure to Advertisements for GERD Medications and the Use 
of Prescription Drugs 
Takes Prescription Does Not Take Prescription p-Value 
Medication Regularly Medication Regularly 
Low Level of Exposure to Yes = 45 (26.8) Yes ~ 13 (1.8» 0.2367 
HeartbumIReflex Ads ' No = 105 (62 .5) No ~ 15 (8 .9) 
Moderate Level of Exposure Yes = 20 (24.1) Yes = 3(3.6) 0.3727 
to Heartburn/Reflex Ads ' No = 45 (54.2) No = 15 (18.1) 
High Level of Expos~e to Yes = 12 (21.82) Yes = 25 (45.45) 0.3353 
HeartbumIReflex Ads ' No ~ 3 (5.45) No ~ 15 (27.27) 
Number of SubJects (percentage) 
We also investigated the relationship between taking over the counter medication 
regularly and the level of exposure to advertisements for heartburn/reflux. The subject population 
who reported having a low, moderate, or high level of exposure to heartburn/reflux ads was not 
statistically more likely to already be taki ng OTe medications. Please see Figure 22. 
Figure 22- Relationship Between Levels orExposure to Advertisements for GERD Medications and the Use 
orOTe Drugs 
Takes OTC Medication Does Not Take OTC p-Value 
Regularly Medication Regularly 
Low Level ofE;t(posure 10 Yes = 29(17.3) Yes = 2( 1.2) 0.5316 
HeartbumlRefle;t( Ads · No= 121 (72.0) No = 16 (9.5) 
Moderate Level of Exposure to Yes - 13(l5.7) Yes - 2(2A) 0.5047 
1·leartbumlReflex Ads· No = 52 (62.7) No >; 16 (19.3) 
High Level ofExposurc to Yes = 7 (12.73) Yes " 30 (54.55) 0.7017 
HeartburnlReflex Ads · No = 2 (3.64) No'"' 16 (29.09) 
Number of Subjects (percentage) 
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EXPOSURE TO HEARTBURNIREFLUX ADS VS. EXPOSURE TO MEDICA nON ADS 
We investigated the relationship between exposure to ads for medications in general and 
exposure to ads for specifically heartburn/reflux. In this case, we looked at the answers to 
questions 4 (familiarity with ads for medications) and 7 (familiarity with ads for heartburn/reflux 
meds). The subject population who reported being exposed to ads for medications in general was 
statistically morc likely to be familiar with ads specifically for heartburn/reflux meels. Please see 
Figure 23. 
Figure 23- Relationship Between Familiarity with Ads [or Medications and Familiarity with Ads 
Specifically (or GERD 
Familiar with ads for Not familiar with ads for p-Value 
heartburn/reflux meds heartburn/reflux meds 
Familiar with ads for Yes = 141 (83.9) YeS'" 14 (8.3) 0.0360 
medications 
. 
No =· 9 (5.4) No'"" 4 (2.4) 
-
Number of SubJecls (percentage) 
EXPOSURE TO HEARBURNIREFLUX ADS + USE OF GERD MEDICATIONS 
Finally, we looked at the relationship between subjects who reported a high level of 
exposure and have taken medications for GERD symptoms. In the population of subjects who 
reported a high level of exposure to heartburn/reflux ads and have taken a medication for GERD 
symptoms, there was no statistical significance between the mean scores of subjects who reported 
h~artbum symptoms and those who did not, as well as between the mean scores of subjects who 
reported regurgitation symptoms and those who did not. 
Please see Figure 24. 
Figure 24· Relation.ship Between High I.evel o{£.xposure to Heartburn/reflux Ads and Have Taken Medications {or 
CERD 
Heartburn -Value Rc ur italion P-Value 
High Level of Exposure 10 Yes '"' 2.67 (2.8) 0.5559 Yes = 4.33 (4.4) 0.9231 
Heartburnlrenux Ads and 1·lave Taken No = 4.0 (2.8) No = 4.0 (2.8) 
Medications for GERD • 
Mean (standard deVlallon) 
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DISCUSSION 
Prevalence of GERD 
In this study. we determined the prevalence of GERD in the young adult population that 
we examined to be between 1.79% and 8.92%, depending on the symptom used. Research has 
determined a varying prevalence in an older population of values of anywhere between 5% and 
45%, depending on the method of diagnosis, with these values increasing over time. However, 
most of this research has been done on a subject group with a mean age in the 40's or 50's, and 
very little research has been done on the prevalence ofGERD in a young ad ult population in the 
Western hemisphere. It has been indicated that close to 50% of adults who experience end-stage 
compl ications ofGERD (including Barrett esophagus) deny symptoms earlier in life. Thus, we 
also wanted to determine whether the young adult population self-reports GERD symptoms, in 
order to determine whether there is recall bias among the older asymptomatic population with 
end-stage complications or whether they are truly asymptomatic. 
In this population, we found that the prevalence of GERD symptoms depended on the 
characterizations used for diagnosis. 17.9% - 24.4% of the subject population reported heartburn 
symptoms at any point during their li ves, while 27.4% - 36.9 % reported regurgitation symptoms 
at any point. However, when making this diagnosis more stringent by including the actual scores 
from the questionnaire, these values decreased. First, when using a cutoff score of 6 (which 
corresponded to either mild symptoms less than one day a week or very mild symptoms one day a 
week), 20.24% of the subject population reported heartburn symptoms, 27.38% reported 
regurgitation symptoms, and 9.52% reported both heartburn and regurgitation symptoms. When 
making the diagnosis more stringent by using a cutoff score of 8 (which represented mild 
symptoms at least one day a week), 3.57% reported heartburn symptoms, 8.92% reported 
regurgitation symptoms, and 1.79% reported both heartburn and regurgitation symptoms. Both of 
these cutoff scores are clinically relevant and would probably warrant treatment by a physician. 
Since GERD is usually a clinical diagnosis with no further invas ive tests, we believe that these 
prevalence values are valid . 
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The prevalence values found in our study are lower than those found in many studies that 
have determined the prevalence in adult populations. This difference may have several 
explanations. One possible contributing fac tor is obesity. A higher BMI is a risk factor for GERD, 
and is a lso more common with increased age. Thus, it may be that the young population 
examined in this study have a lower BMI than the older populations examined in many of the 
other studies, and therefore do not possess this risk factor. The difference in preva lence may also 
simply be due to.a lower self-perception of disease symptoms in a younger population versus an 
older one, as it is often assumed that young people arc less attuned to physical symptoms of 
di sease. In addition, an older population may be fo llowed by physic ians more regu larly, and thus 
may have to examine any symptoms more frequently. In contrast, the younger population 
examined in this study may not be exposed to this level of health care as frequently. Without the 
impetus by a medical care-giver to examine their physical well-be ing, the younger population 
may be less likely to notice any symptoms of disease. Noted before was the statistic that a high 
percentage of older adul ts who experience the end-stage complications of GERD deny symptoms 
while younger. Perhaps some subjects in the young population have the pathophysiologic factors 
th at lead to gastroesophageal reflux, but for an unknown reason, do not experience the symptoms 
of this reflux. The population in this study is a we ll educated group in college. The study by Somi 
et al that examined a young population in Iran indicated that the self-reporting of GERD 
symptoms was lower in subjects " in high rank fie lds." F inally, there was a hi gher percentage of 
females than males in our study group. Since males are more like ly than females to suffer from 
GERO, perhaps the decreased percentage of males parti cipating in the study caused a decrease in 
the overall preva lence of GERD found in the population that we used. 
Inte restingly, the prevalence va lues found in thi s study are also lower than those found in 
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the study by Sami et. Qualifications in comparing these two studies include the use of different 
questionnaires. In addition, their study reported values for experiencing symptoms either weekly 
or monthly, which are less stringent qualifications than those used in OUf study. Nonetheless, it is 
interesting that the prevalence differs between the two studies. Several studies have determined 
different prevalences in -different" populations. For example, the prevalence ofGERD has been 
determined to be lower in Asian populations than in populations from the Western hemisphere, 
with possible unknown genetic factors contributing to this difference. However, Middle Eastern 
populations and populations in the Western hemisphere have not yet been compared. Unknown 
genetic or cultural factors may playa role in this difference. 
Relationship Between Direct to Consumer Marketing and the Self-Perception of GERD 
Symptom"s 
In our study, we also investigated the complicated relationship between exposure to 
advertisements for medications and the self-perception of GERD symptoms. The growing 
presence of direct-to-consumer advertisements has already noted to playa role in patients' 
perception of disease. Research indicates that sometimes, such advertising may not present clear 
and unbiased information to the consumer. Benefits to DTC marketing for GERD medications 
include patient education. Jt is possible that a person who otherwise would not pay attention to 
their GERD symptoms and thus would possibly progress toward complications of the di sease, 
including esophageal adenocarcinoma, would now visit their physician in order to get treatment 
for their heartburn/reflux. Thus, the benefit to DTC marketing includes the possible decrease in 
future compli cations of GERD, including adenocarcinoma. The risks to DTC marketing include 
the use of unnecessary medications. No medication is without side effects, and the use of a drug 
cou ld lead to unnecessary complicati ons. The unwarranted use of GERD medications also 
increase health care costs, through higher.costs for insurance plans that cover these medications. 
We wanted to determine whether the young adult population is influenced by DTC marketing for 
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GERD medications. 
It is worth mentioning that the population used in this study did report a very high level 
of exposure to advertisements for medications in general with 92.3% of the group noting that they 
had been exposed, mostly through television, magazines! newspapers, and the internet. In fact, 
54.2% were able to recall the specific names of these medications, mostly for drugs for sexual 
disorders. On this background of a very high level of exposure to advertisements for medications, 
a high percentage (89.29%) reported exposure to ads for heartburn/reflux medications, with those 
subjects who reported a high level of exposure to advertisements in general more likely to report 
a high level of exposure to advertisement specifically for heartburn/reflux medications. Of this 
population, 36.3% reported being able to recall details of these advertisements. Interestingly, the 
s logan "The purple pill" was the most commonly recalled detail, recorded by 32.3% of the 
population that reported exposure to ads. It is often assumed that a young, healthy population 
does not pay attention to those advertisements associated with disease or illness. However, with 
36.3% of our study group reporting exposure to ads and 36.4% of that population able to reca ll 
specific details, it is clear that direct-to-consumer marketing for heartburn/reflux medications is 
being noticed by this young population. The specific slogan "The purple pill" is often labeled as 
an effective advertisement -- it is clear that the young population examined in this study 
remembers this catchphrase, and Nexium was, in fact, the most recalled medication. Thus, it 
~ppears that this catchphrase is effective advertising, because the public is able to remember the 
medication it is promoting. 
Despite the fact that this young adult population is aware of advertising for 
heartburn/reflux medications, it does not appear that such advertising is linked to the self-
perception of GERD symptoms. Using varying levels of stringepcy for the diagnosis of 
s ignificant clinical symptoms (both mild symptoms one day a week and either mild symptoms 
less than one day a week or very mild symptoms one day a week), there was no statistically 
s ignificant relationship between exposure to advertising and GERO symptoms. Thus, while 
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advertising appears to be effective in the products are highly reca lled, advertising does not appear 
to affect the young adult population's self-perception of disease symptoms. 
Although 12.5% of the subject group believed that advertisements for medications had 
influenced their approach to heartburn/reflux symptoms (answered yes to question 14), there was 
also no statistically sign ificant relationship between answering yes to this question and the self-
perception of GERD symptoms. Thus, there appears to be a disconnect between the way this 
population feels that advertising has affected them and their actual perception of disease 
symptoms. Fina lly, it does not appear that a high level of exposure to heartburn/reflux ads 
corresponds with the use of GERD medications or a higher perception of GERD symptoms. 
However, interestingly, there do.es appear to be a relationship between the self-perception 
of GERD symptoms and the actions of those who report such symptoms. Subjects who had seen a 
physician' for GERD symptoms were more likely to report heartburn and regurgitation symptoms. 
It may be that the subjects who report GERD symptoms are those people who are more sensitive 
to any symptom, and thus would be more like ly to seek out care. 
The lack of a relationship between exposure to DTC marketing and the self-perception of 
GERD symptoms may have several causes. First, the population used in this study is highly 
educated. Perhaps with education comes skepticism of advertisements, since education at these 
high levels is often taught through continua lly questioning everything. Though these young 
s~dents may be exposed to the ads and retain the information promoted by the ads, they may be 
more like ly to view such information with skepticism, such that they question the va lidity of the 
ads. If this is true, they are less likely to be innuenced. 
Limitations 
Severa l limitations are present in this study. The first limitation concerns the 
questionnaire itself. While several of the questions were borrowed from a previously validated 
questionna ire, the other questions have not been va lidated. The additional questions may also 
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affect the validity of the borrowed questions. In addition, using a survey questionnaire may lead 
to subject bias. The subjects that completed the questionnaire may have been those subjects more 
likely to have stronger opinions on the questions asked. 
The second limitation concerns the patient population used in this study. First, the 
characteristics of the population used may not allow for the application of the results from this 
study to the entire young adult popu lation. The subjects in this study were young, highly-educated 
adults, and as such, represent a discrete population. The effects of soc ioeconomic status and leve l 
of education on the self-perception of disease may mean that the results found for this population 
may not be applicable for a different young adult popu lation. Another limitation concerns the 
group size. The populations for several ~fthe specific sub-groups at which we looked were very 
small . Statistical analysis of populations this small may lead to a skewed view of the data. 
Conclusion 
Despite these limitations, this study demonstrates a low prevalence ofGERD symptoms 
in a young adult population. In addition, it appears that there is no relationship between direct to 
consumer marketing and exposure to advertisements for medications and self perception of 
GERD symptoms in this population. 
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GERD questionnaire 
Age (yes) __ Gender ( M IF) 
1. Please answer each of the following 2 questions by checking~ box per row. 
Thinking about your symptoms over the last 4 weeks, how often did you have the following? 




b. Pain behind 
your 
breastbone 
c. An acid 








Did nOI have . Less than one:, 







I ' , 
0 1 
Di 
02 I?i' .:;' . ~~.. ", 
'. 
04 
02 OJ 04 
D2 OJ 04 
. 
Thinking about your symptoms over the last 4 weeks, how would you rate the following? 
Did not have Very Mila Mild Moderate Moderately , 
,. ft. burning 
fee ling behind DO 0 1 D2 OJ 
your 
breastbone ". 
b, Pain behind DO 01 02 OJ 
your 
breastbone ....... , .. , • , ,. An acid taste DO 01 , . D2 .~"D3 · 
in your mouth .. 
. , . ", 
d. Unpleasant " . . 
movement of -'". 
material DO 01 > D2 03 
upwards from 
the stomach .. 
2. Do you take any prescription medications regularly ( Yes I No ) 
If yes, please list them: 
• 
3. Do you take any over the counter medications regularly? ( Yes I No ) 












O S " , 
If yes, in which media fannals have you seen these advertisements? (Check all that apply.) 
magazines, newspapers television 
internet radio 
5. Do you recall what conditions they treat? ( Yes I No ) 
Jfyes, please list them: 
6. Do you recall the names of any of the medications? ( Yes I No ) 
J[ yes, please list them: . 
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7. Have you seen advertisements for medications for heartburn or acid reflux? ( Yes I No ) 
Jf yes, in which media formats have you seen these advertisements? (Check all that apply.) 
magazines, newspapers television 
internet radio 
8. Do you recall the names of any of the med ications? ( Yes I No ) 
1fyes, please list them: 
9. Do you recall any detai ls (catchphrases, scenarios) of the advert isements? ( Yes I No ) 
Jfyes, please list them: 
10. Have you taken any medications for heartburn or acid reflux? ( Yes I No ) 
Jfyes, please list them: 
11 . Have you seen a physician for heartburn or acid reflux symptoms? ( Yes I No ) 
12. Have you rece ived a prescription medication for heartburn or acid reflux? ( Yes I No ) 
13. How frequently do you use medications for heartburn or acid-reflux? 
never every 4-6 months every 2-4 months 
every 1-2 months weekly several times a week 
14. Have advertisements for med ications influenced your approach to heartburn or acid reflux 
symptoms? (Check a ll that apply.) 
encouraged you to start using medication for heartburn/reflux 
encouraged you to use your medicat ion more frequently 
encouraged you to change your medication 
increased your concern for a serious underlying medical condition 
led you to see a doctor for heartburn/reflux symptoms 
15. Do you smoke cigarettes? ( Yes I No ) 
Jfyes, how many packs per day? 
16. Do you drink alcohol? ( Yes I No ) 
ffyes, how frequently? 
never __ 2-3 times a year _ _ 2-3 times a month __ 2-3 times a week __ daily 
Thank you! 
